Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Nutanix Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.32 (market cap $4.59B), while Nutanix Inc trades at $73.34 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 4.3× Definium Therapeutics Inc. Common Shares's market cap, and Nutanix Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Nutanix Inc for 17 Days on average.
| DFTX | NTNX | |
|---|---|---|
Market Cap | $4.59B | $19.78B |
Volume | 2,103,937 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $48.45 | $73.42 |
52-Week Low | $10.68 | $34.41 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $3.55B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nutanix (NTNX) trades at $73.24, down slightly by 0.25% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive profitability with an 86.8% gross margin. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms, supporting positive market sentiment.
The investment outlook remains positive with a consensus price target of $76.11 representing 4% upside potential. Key opportunities include external storage partnerships and AI growth initiatives, while risks involve high valuation multiples (EV/EBITDA of 46.22) and negative ROE of -395.76%. Institutional ownership trends and 62.5% analyst buy ratings suggest continued Wall Street confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
